〔Abstract〕 Objective To study the effect and mechanism of liposomal curcumol(LC) combined with cisplatin on human ovarian cancer cells. Methods The experiment took ovarian cancer cell lines SKOV3and HO8910 as the research objects, combined with different concentrations of cisplatin(0,2,4,8,16,32,64) μg/ml based on 10 μg/ml LC for grouping. MTT,Transwell and flow cytometry assay were used to detect cell proliferation, invasion, migration and apoptosis ability respectively in each group.Western blot assay was used to detect AKT,p-AKT and cleaved Caspase 8,9,3 protein expression in each group. Results MTT results showed that compared with the cisplatin alone or LC group, the tumor cell proliferation rate of the combined drug group reduced(P<0.05),the IC50of cisplatin to SKOV3in the combination was(12.67±2.03) μg/ml(vsthe IC50of cisplatin alone:(38.28±5.98) μg/ml, the IC50of cisplatin to HO8910 in the combination was(10.55±1.55) μg/ml [vsIC50of cisplatin alone:(26.41±2.30) μg/ml]. In the combination group(8 μg/ml cisplatin+10 μg/ml LC),the invasion and migration rates of ovarian cancer cells reduced(P<0.05),and the apoptosis rate was the highest(P<0.05). Western Blot results showed that the expression level of p-AKT protein in ovarian cancer cells in the combined drug group decreased(P<0.05),and the protein levels of cleaved-Caspase8,9,3 increased(P<0.05). Conclusion Low-dose LC can enhance the ability of cisplatin to inhibit the proliferation, migration and invasion of human ovarian cancer cells, and promote tumor cell apoptosis.The combination of drugs may promote apoptosis of ovarian cancer cells through the PI3 K/AKT pathway.